Time to Reconsider AC Immune SA (NASDAQ:ACIU) After More Short Sellers?

June 16, 2018 - By Winifred Garcia

The stock of AC Immune SA (NASDAQ:ACIU) registered an increase of 2.67% in short interest. ACIU’s total short interest was 1.71 million shares in June as published by FINRA. Its up 2.67% from 1.66M shares, reported previously. With 37,500 shares average volume, it will take short sellers 46 days to cover their ACIU’s short positions. The short interest to AC Immune SA’s float is 7.91%.

The stock increased 4.58% or $0.42 during the last trading session, reaching $9.6. About 20,995 shares traded. AC Immune SA (NASDAQ:ACIU) has risen 16.72% since June 16, 2017 and is uptrending. It has outperformed by 4.15% the S&P500.

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has market cap of $551.05 million. The Company’s SupraAntigen and Morphomer platforms generates antibodies and small molecules that selectively bind to misfolded proteins to address neurodegenerative indications, such as AlzheimerÂ’s , ParkinsonÂ’s, down syndrome, and glaucoma diseases. It currently has negative earnings. The companyÂ’s lead product candidate is crenezumab, a humanized, monoclonal, and conformation-specific anti-Abeta antibody, which is in Phase 3 clinical studies.

More news for AC Immune SA (NASDAQ:ACIU) were recently published by: Nasdaq.com, which released: “Research Report Identifies AC Immune SA, Vipshop, Infosys, STMicroelectronics NV, BRF SA, and National Steel with …” on June 08, 2018. Benzinga.com‘s article titled: “44 Biggest Movers From Yesterday” and published on June 05, 2018 is yet another important article.

AC Immune SA (NASDAQ:ACIU) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: